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This retrospective study was undertaken to determine the usefulness of intra-
venous regional anesthetic (IVRA) blocks containing ketorolac and lidocaine in
the management of sympathetically-mediated pain, and to determine what fac-
tors, ifany, predicted success with this technique. Sixty-one patients with reflex
sympathetic dystrophy presenting to a university-affiliated teaching hospital's
pain management center were evaluated. Patients underwent one or more treat-
ments with IVRA blocks containing ketorolac and lidocaine. The duration of
pain, site of extremity affected, pain symptomatology, duration of relief from
the first IVRA block, absence of pain following a series of IVRA blocks and
side-effects from the IVRA blocks were determined. Ofthe 61 patients, 16 had
complete response (26 percent), 26 had a partial response (43 percent) and 19
had no response (31 percent) to theketorolac-containing IVRA. The only symp-
tom,which predicted a failure with this therapy was allodynia. No patient had
serious side effects from the IVRA block; dizziness following tourniquet release
occurred in 41 percent (n = 25) ofthe patients. IVRA block containing ketoro-
lac is a useful and minimally invasive technique for the management ofpatients
with reflex sympathetic dystrophy.
INTRODUCTION
The multitude oftherapeutic modalities that have been advocated for the treatment of
sympathetically-mediated pain attests to therelative lack ofefficacy anddifficulty oftreat-
ment. Intravenous regional anesthetic (IVRA)C block is one such therapeutic technique,
and a variety of agents have been used in conjunction with local anesthetics, including
guanethidine, steroids and ketorolac [1-7]. Over the past year, we have utilized a combi-
nation of ketorolac and lidocaine for IVRA blocks in the treatment of 61 patients pre-
senting with sympathetically-mediated pain. Wereporthere the results ofourmanagement
of these patients.
MATERIALS AND METHODS
Institutional human investigational committee approval was obtained prior to per-
forming this retrospective chart review. Informed consent was obtained from all patients
prior to procedural intervention. Patients were offered an IVRA block ifthey had clinical
symptoms of sympathetically-mediated pain (i.e., allodynia, hyperalgesia, hyperpathia,
edema, vasomotor changes, pain with a burning quality, sudomotor changes or tempera-
ture difference between extremities).
A 22-g catheter was inserted in a vein ofthe affected extremity, and the catheter was
flushed with 3 ml of a heparinized (10 u/ml) solution. Intravenous access then was estab-
lished with a peripherally placed 20-g indwelling catheter in the contralateral extremity.
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After application of routine monitors (including electrocardiogram, pulse oximeter and
oscillometric non-invasive blood pressure cuff), the painful extremity was exsanguinated
by elevating the extremity and wrapping it with an Esmarch bandage. A single tourniquet
was placed on the upper arm and was then inflated to 300 mm Hg. Following removal of
the Esmarch bandage, 52 ml of solution containing 60 mg (2 ml) of ketorolac and 50 ml
of0.5 percent lidocaine was administered intravenously via the 22-g catheter. The tourni-
quet was kept inflated for a minimum of 30 min after injection. All patients were moni-
tored for an additional minimum of60 min prior to discharge from the clinic.
IVRA blocks were offered to each patient up to six times (maximum of once a week
for six weeks). Success was defined as a complete resolution ofpain not requiring inter-
ventions other than the IVRA block (responders group). Partial success was defined as a
resolution of the pain that was not long-lasting. A failure was defined as no subjective
improvement following the IVRA block. Partial success and failure patients were classi-
fied as "non-responders." If there were no beneficial effects obtained, or if the patient
desired, other types oftherapeutic intervention were offered (e.g., stellate ganglion block,
peripheral nerve blocks, brachial plexus blocks, etc.).
The duration of the pain symptoms was noted prior to administration of the IVRA.
The therapeutic benefits of the IVRA blocks were evaluated in all the patients; benefits
were also separately evaluated in patients with a duration of symptoms less than, and
greater than, six months. Using chi-square analysis, the presence or absence of an
antecedent insult (surgery, traumaorboth) was evaluated in an attemptto determine which
patients benefited from the IVRA block. The symptoms that resulted in patient referral to
the pain clinic were noted, and chi-square analysis was used to determine which ofthese
symptoms correlated with success or failure of the IVRA blocks. Data were analyzed
using unpaired t-test todetermine which demographic characteristics were associated with
a high probability oftherapeutic success.
The duration ofthe pain state was compared between the responders and non-respon-
ders using an unpaired t-test. The duration of success ofthe first IVRA block was evalu-
ated similarly. The number of IVRA treatments received by patients in each group was
compared using Mann-Whitney U test.
Data are presented as mean ± SD or mean (10th to 90th percentiles), where appro-
priate. For all evaluations, p < .05 was considered statistically significant.
RESULTS
Demographics of the patients are presented in Table 1. There was no significant dif-
ference between the two groups with respect to any ofthe demographic data.
Of the patients who presented to the pain center, 16 (26 percent) had complete
response with the IVRA, 26 (43 percent) had a partial response and 19 (31 percent) had
no response. The duration of follow-up is presently 18 months for all patients, and none
ofthe complete responders has required further therapy.
Table 1: Age, height, and weight of all patients, complete responders and non-responders.
Patients who achieved either partial success or failure from the IVRA were classified as "non-
responders."
Number Age Height (in) Weight (kg)
All patients 61 44 + 17 66 + 4 76 + 28
Complete responders 16 51 + 17 67 + 4 85 + 26
Non-responders 45 41 + 17 66 + 4 72 + 28
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The responders had a median of four (1-6) treatments, whereas the non-responders
had a median of one (1-4) treatment (p = .016). If no benefit was realized from the first
IVRA block, we tended not to perform a series of IVRA blocks.
The patients who presented to the pain clinic and participated in this evaluation had
a mean duration ofpain symptoms of 80 ± 146 weeks. The responders had a mean dura-
tion of pain of 44 ± 84 weeks, while the non-responders had a duration ofpain of 93 ±
161 weeks (p = NS). Three patients achieved complete reliefwith the firstIVRA treatment
and were subsequently discharged from the pain clinic. The duration ofpain in these three
patients was 12, 12 and 56 weeks, respectively. Of the other patients who achieved com-
plete degree ofreliefafter more than one IVRA treatment, the duration ofrelieffollowing
the first IVRA was 3.6 ± 2.1 days, whereas in the non-responders, the mean duration of
pain reliefwas 2.2 ± 3.1 days. There was no significant difference between the responders
and non-responders with respect to the duration ofrelief following the first IVRA.
When only evaluating patients who had pain for less than six months, 12 of 32 (38
percent) patients achieved complete success, 13 patients achieved partial success (40 per-
cent), and seven patients were classified as failing to respond (22 percent).
When evaluating the symptoms with which the patients presented to the pain clinic,
the only symptom that significantly predicted a lowerchance ofcomplete success with the
IVRA was the presence of allodynia (p < .024). Of the 22 patients who presented with
allodynia, only two (9 percent) experienced complete relief, whereas 14 ofthe 49 patients
(29 percent) without allodynia had complete relief. The following signs and symptoms
were not associated with a higher or lower chance of success following IVRA: burning
pain, edema, skin color changes, sweating changes, temperature changes, hyperalgesia
and hyperpathia. Similarly, site of affected extremity (upper vs. lower) and history of
antecedent trauma or surgery were not significant predictors of success of IVRA.
No patient had alife-threatening side effect from the IVRA block. Ofthe side effects,
dizziness and lightheadedness upon deflation of the tourniquet occurred in 41 percent (n
= 25) ofthe patients. These symptoms were unaccompanied by significant hemodynamic
changes. The next most common complaint was a numb extremity following deflation of
the tourniquet (16 percent, n = 10 patients). Three patients (5 percent) experienced nausea
upon release of the tourniquet. All side effects completely resolved within one-half hour
following tourniquet deflation.
DISCUSSION
The use of intravenous regional anesthesia in the management of sympathetically-
mediated pain is not new. Previous reports have documented success with injectates con-
taining lidocaine and solumedrol [5, 7], bretylium [8], guanethidine [2], reserpine [9],
ketorolac and lidocaine [1], and non-steroidal anti-inflammatory drugs in saline [1,4]. We
have previously used IVRA blocks with solutions containing solumedrol but were con-
cerned about systemic side effects due to multiple doses ofsteroids over a relatively short
period oftime. IVRA blocks with bretylium had been part of our therapeutic practice but
were discontinued because of the high incidence of orthostatic hypotension, which pre-
vented the discharge ofourpatients from the outpatient clinic in atimely fashion. We have
not utilized guanethidine and reserpine in our practice because of the lack of availability
of these intravenous medications in the United States. Thus, our therapeutic choices of
IVRA injectate for the treatment of sympathetically-mediated pain are limited to local
anesthetics and ketorolac.
The one previous report utilizing IVRA with ketorolac detailed their experience in
seven patients. Only oneofthese patients hadcomplete reliefofsymptoms (this onepatient
had 36 days of relief, which was continuing at the time of the report) [1]. It is thus inter-
esting to note that 26 percent of ourpatients experienced complete relief. This is similar to
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the incidence of complete relief reported with stellate ganglion blockade [10] or with
guanethidine IVRA blocks [2]. However, the success rates from individual reports are dif-
ficult to compare because ofthe patients' varying severity and duration ofsymptoms when
referred to different pain management centers. In addition, stellate ganglion blocks also
may have significant morbidity such as pneumothorax, subarachnoid block and vertebral
artery injection. Furthermore, such blocks may be relatively contraindicated in the antico-
agulated patient. Based on the results reported presently, we feel that the risk of IVRA is
much lower, while the only major side effect was dizziness upon tourniquet deflation,
which was short-lived and did not prolong discharge from our pain clinic.
The issue arises whether the relief obtained in our center resulted from the lidocaine
or the ketorolac in the IVRA. We believe that the therapeutic benefit is derived from the
use of ketorolac. Vanos et al. [1] found that IVRA block containing ketorolac was suc-
cessful and that the combination with lidocaine provided short-term additional analgesia,
allowing the patients to undergo physical therapy. We do not think that the lidocaine alone
resulted in significant long-term benefit. Hord et al. [11], who combined lidocaine with
bretylium, found that the lidocaine IVRA blocks produced a mean pain reliefof2.7 days,
whereas the combination with bretylium produced a mean relief of 20.0 days.
Furthermore, McKain et al. [12] found that lidocaine IVRA failed to produce pain relief
beyond the duration ofthe block. There is thus a general consensus that IVRA blocks that
only contain lidocaine will provide short-term relief and that the mixture of two drugs is
necessary for prolonged relief.
It is impossible to state emphatically that the results in our patients were due to
ketorolac, and not from lidocaine or the combination ofthe two; however, when ketorolac
was diluted with normal saline rather than lidocaine, similar results have been reported
[1]. We do believe that lidocaine is a useful part ofthe injectate; in our patients who were
classified as IVRA "failures," the IVRA lidocaine allowed them to successfully complete
a physical therapy session.Also, the lidocaine decreased the burning ofketorolac on injec-
tion and also raised the threshold for tourniquet pain.
The precise cellular mechanism responsible for the alteration in peripheral nocicep-
tor sensitivity following tissue trauma are not known [13]. Chemical mediators such as
prostaglandins are believed to modify nociceptor input leading to mechanical allodynia
[14]. The only symptom that was predictive offailure with IVRA lidocaine and ketorolac
was allodynia. Success of ketorolac in these patients would thus be expected by an inhi-
bition ofthis peripheral sensitization; this, however, was not the case in our patients.
The dose ofketorolac was arbitrarily chosen; an increase or decrease in the dose may
affect the results. The one previous report of the use of IVRA ketorolac also used 60 mg
[1]. It remains to be determined whether a lower dose may achieve the same effect, or if
a higher dose may result in a greater percentage of complete responders. It also remains
to be determined whether systemically, rather than locally, administered ketorolac may be
an effective treatment.
In conclusion, we have presented our results of IVRA blocks containing ketorolac
and lidocaine in the management of sympathetically-mediated pain states. Approximately
69 percent of the patients had at least partial relief with this therapy. Of all patients, 26
percent had complete resolution oftheir pain symptoms, while the side effects were min-
imal and short-lived.
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